Stock data
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX) reported net income of -US$167.79M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$191.41M | -US$167.79M | — |
| 2024 | — | — | -US$158.83M | -US$133.81M | — |
| 2023 | — | — | -US$114.36M | -US$100.16M | — |
| 2022 | — | — | -US$71.66M | -US$67.64M | — |
| 2021 | — | — | -US$43.22M | -US$42.81M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$57.33M | — |
| 2026-03-31 | — | -US$49.01M | — |
| 2025-12-31 | — | -US$50.22M | — |
| 2025-09-30 | — | -US$40.67M | — |
| 2025-06-30 | — | -US$36.12M | — |
| 2025-03-31 | — | -US$40.80M | — |
| 2024-12-31 | — | -US$39.66M | — |
| 2024-09-30 | — | -US$34.13M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.